ClinicalTrials.gg
RecruitingNCT07711223Updated Jul 17, 2026

Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

A Phase 1/2 interventional study of ACC017+FTC/TAF and DTG+FTC/TAF in Infection, Human Immunodeficiency Virus, sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2025, registered Jul 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study employs a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group, non-inferiority design. The trial will be conducted in treatment-naïve adult patients with HIV-1, using Dolutegravir Sodium Tablets as the control, to demonstrate the efficacy and safety of the core investigational drug ACC017 combined with FTC/TAF Tablets (II) compared to Dolutegravir Sodium combined with FTC/TAF Tablets (II) in treating treatment-naïve adult HIV-1 patients.

After initial screening eligibility is confirmed, participants will return to the clinic on Day 1 (D1) for re-evaluation of eligibility and completion of required examinations. Eligible participants will be randomized in a 1:1 ratio to receive either ACC017 Tablets (40 mg, once daily [QD]) or Dolutegravir Sodium Tablets (50 mg, QD). Both treatment groups will also receive FTC/TAF Tablets (II) and will undergo 48 weeks of continuous double-blind treatment. Subsequently, all study participants will transition to open-label treatment with ACC017 combined with FTC/TAF Tablets (III) for an additional 48 weeks (during which the dummy medication will no longer be administered).

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's planned enrollment of 660 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Jiangsu Aidea Pharmaceutical Group Co., Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant will be excluded from the trial if they meet any one or more of the following criteria:

  1. Voluntarily sign the written form, demonstrate the ability to understand and comply with the requirements of the study protocol;
  2. Age ≥18 years (inclusive) at the time of providing informed consent, both male and female participants are eligible;
  3. Diagnosed with infection prior to informed consent, and have an HIV RNA viral load ≥500 copies/mL (tested at the local center) at screening;
  4. Have not received any ART since initial HIV diagnosis, and agree not to initiate any ART from the time of informed consent until randomization.

Exclusion criteria

Exclusion Criteria:

  1. Participants judged by the investigator as having poor treatment compliance or protocol adherence, or any other condition making them unsuitable for the study, or when participation may not best protect the participant's health interests;
  2. At screening, female participants who are pregnant, breastfeeding, or have a positive blood pregnancy test; or from 1 month before screening until 3 months after the last dose of the product, participants of (WOCBP) or male participants with plans for procreation (including egg or sperm donation), or unwilling to use effective (including one or more non-pharmacological methods, or absence of heterosexual activity in daily life) or safety measures;
  3. At screening, judged by the investigator to be in the acute phase of -1 infection, or with opportunistic infections or other AIDS-defining conditions within 3 months before screening;
  4. At screening, judged by the investigator to have poorly controlled clinically significant diseases (including cardiovascular, respiratory, digestive, endocrine-metabolic, neuropsychiatric, hematological, and immune systems, etc.), including but not limited to: poorly controlled hypertension despite active treatment (resting SBP ≥160 mmHg or DBP ≥100 mmHg upon retest), Class III or IV cardiac function, GOLD Grade 3-4 , severe liver impairment ( Class C), etc.;
  5. At screening, judged by the investigator to have clinically significant laboratory abnormalities, including but not limited to: (Hb) \<90 g/L, or >5 × , or ALT >3 × ULN with total (TBIL) >1.5 × ULN, or \<30 mL/min ( equation);
  6. At screening, -positive with HBV DNA ≥2000 IU/mL (local center testing), antibody-positive with HCV RNA > LLOQ (local center testing), or judged by the investigator to require anti-syphilis treatment (participants who have completed standardized anti-syphilis treatment for ≥7 days may be considered);
  7. Use of pre-exposure prophylaxis (PrEP) and/or post-exposure prophylaxis (PEP) within 1 month before screening, or prior use of long-acting PrEP drugs (e.g., cabotegravir or lenacapavir, etc.);
  8. Within 30 days before screening, at screening, or planned use during the trial, systemic immunomodulators, cytotoxic drugs, etc. (see Appendix 7), and unwilling or unable to discontinue use from the time of ;
  9. At screening, known history of allergy to the investigational product, structurally related drugs, or ; or history of allergic diseases requiring medication control before screening (e.g., asthma, urticaria, atopic dermatitis [eczema], etc.);
  10. Before screening, major gastrointestinal surgery (except uncomplicated appendectomy or cholecystectomy); or at screening, judged by the investigator as likely to require elective major surgery during the trial;
  11. Within 5 years before screening, history of (except carcinoma in situ of the cervix treated by conization, or surgically cured basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ [Bowen's disease] of the skin);
  12. Within 5 years before screening, history of alcohol, drug, or other substance abuse (non-medical excessive, inappropriate, or addictive use of alcohol, drugs, or other substances leading to social, psychological, or physiological impairment);
  13. Before or at screening, intolerance to venipuncture, history of needle or blood phobia, or blood donation (including component blood) or significant blood loss (≥400 mL) or transfusion within 3 months before screening, or plans to donate blood during the trial;
  14. Participation in any interventional clinical trial (including drugs, vaccines, or devices) within 3 months before screening.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    ACC017/FTC/TAF

    stage 1:Participants receive ACC017 tablets plus emtricitabine/tenofovir alafenamide (FTC/TAF) tablets.

    Drug: ACC017+FTC/TAF

  • Active comparator
    DTG/FTC/TAF

    stage1: Participants receive dolutegravir sodium tablets plus emtricitabine/tenofovir alafenamide (FTC/TAF) tablets.

    Drug: DTG+FTC/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. At 48 weeks of treatment, the percentage of participants with HIV RNA load <50 copies/mL (analyzed using the US FDA Snapshot Approach) (primary analysis).

    Time frame: week 48

Secondary outcomes

  1. Percentage of participants with HIV RNA < LLOQ at Week 48;

    Time frame: week 48

  2. Percentage of participants with HIV RNA <200 copies/mL at Week 48;

    Time frame: week 48

  3. Percentage of participants with HIV RNA <50 copies/mL at Week 24;

    Time frame: week 24

  4. Percentage of participants with HIV RNA < LLOQ at Week 24;

    Time frame: week 24

  5. Absolute change from baseline in log10-transformed HIV RNA at Week 4;

    Time frame: week 4

  6. Absolute change from baseline in log10-transformed HIV RNA at Week 8;

    Time frame: week 8

  7. Absolute change from baseline in log10-transformed HIV RNA at Week 12;

    Time frame: week 12

  8. Percentage of participants with HIV RNA <50 copies/mL at Week 96 (final analysis);

    Time frame: week 96

  9. Percentage of participants with HIV RNA < LLOQ at Week 96.

    Time frame: week 96

  10. Absolute change from baseline in CD4+ cell count at Week 48 (cells/μL);

    Time frame: week 48

  11. Percentage of participants with an increase from baseline in CD4+ cell count of ≥100 cells/μL or ≥30% at Week 48;

    Time frame: week 48

  12. Absolute change from baseline in CD4+ cell count at Week 96 (cells/μL).

    Time frame: week 96

  13. TEAEs (including ADRs, grade ≥3 AEs/ADRs, SAEs/SADRs, AEs/ADRs leading to treatment discontinuation/early trial withdrawal)

    Number and percentage of participants with treatment-emergent adverse events (TEAEs), including those with adverse drug reactions (ADRs), grade ≥3 TEAEs, grade ≥3 ADRs, serious adverse events (SAEs), serious adverse drug reactions (SADRs), and TEAEs/ADRs leading to treatment discontinuation or early trial withdrawal, during the study period.

    Time frame: week 1 - week 48; week 1 - week 96

  14. changes in vital signs

    Number of participants with treatment-emergent clinically significant abnormalities in vital signs. Parameters assessed include systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and body temperature. Clinical significance is determined by the investigator according to protocol-specified criteria.

    Time frame: week 1 - week 48; week 1 - week 96

  15. Number of Participants with Clinically Significant Abnormal Physical Examination Findings

    Number of participants with treatment-emergent, clinically significant new or worsened abnormalities on physical examination, as assessed by the investigator across major body systems.

    Time frame: week 1 - week 48; week 1 - week 96

  16. Number of Participants with Clinically Significant QT Interval Prolongation on 12-Lead ECG

    Time frame: week 1 - week 48; week 1 - week 96

  17. Number of Participants with Clinically Significant Laboratory Test Abnormalities

    Number of participants with treatment-emergent clinically significant abnormalities in hematology and chemistry laboratory parameters. Individual parameters include hemoglobin, white blood cell count, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and serum creatinine. Clinical significance is determined by the investigator based on predefined criteria.

    Time frame: week 1 - week 48; week 1 - week 96

  18. Number of Participants with Changes in Concomitant Medications

    Number of participants with any new initiation, dose adjustment, or discontinuation of concomitant medications during the study period.

    Time frame: week 1 - week 48; week 1 - week 96

Other outcomes

  1. Evaluation of integrase strand transfer inhibitor resistance-associated mutations(INSTI RAM) change from baseline through Week 48;

    Time frame: week 0 - week 48

  2. Evaluation of NRTI RAM change from baseline through Week 48;

    Time frame: week 0 - week 48

  3. Plasma Trough Concentration (Ctrough) of ACC017

    Plasma trough concentration (Ctrough) of ACC017, defined as the pre-dose concentration at steady-state, measured at Week 4, Week 12, Week 24, and Week 48.

    Time frame: week 0 -week 48

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Aug 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 17, 2026
StartActual
Nov 7, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07711223
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Nov 7, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Qin Hong
Contact
qinh@aidea.com.cn
+862583193135
Zhou F Mei
Contact
zhoufamei@aidea.com.cn
18783835123
Zhang F Jie, M.D., Ph.D.
principal investigator · Beijing Ditan Hospital
Cai W Ping, M.D., Ph.D.
principal investigator · Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ACC017 · Emtricitabine · Tenofovir alafenamide

Start the discussion